Full Press Release Details
Announces Update on Omburtamab for DIPG
NY, June 4, 2021 (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB)
a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products
for the treatment of cancer, today announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center ("MSK")
and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma ("DIPG")
at the American Society of Clinical Oncology ("ASCO") Virtual Annual Meeting on June 4, 2021
phase 1 dose-escalation study with administration via convection enhanced delivery ("CED"), showed that dosing of omburtamab
radiolabeled with 8 mCi of 124-Iodine appeared to be well-tolerated and provided distribution volume to potentially cover tumor volumes
of up to 20 cm3. The median overall survival of all 46 patients in the study increased by three to four months as compared
to the historical control group. The study will continue dose escalation for both infused volume and dose.
are excited to share these results that significantly broaden the potential reach of omburtamab, which would be addressing a clear unmet
medical need. The results pave the way for our multicenter phase 2 study in DIPG later this year, where we expect to give up to
three repeated doses of omburtamab," stated Thomas Gad, founder, Chairman and President.
Dr. Claus Moller, Chief Executive Officer, continued,
"We are expanding our omburtamab franchise significantly this year. While the iodine labeled omburtamab targets DIPG, CNS/LM from
neuroblastoma and DSRCT, we have also initiated clinical trials for medulloblastoma and B7-H3 positive CNS metastasis with our lutetium
labeled omburtamab."
Researchers at MSK developed omburtamab, which
is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the
Y-mAbs is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The
Company has a broad and advanced product pipeline, including including one FDA approved product, DANYELZA (naxitamab-gqgk), which
targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development,
commercialization and product distribution plans; current and future clinical and pre-clinical studies and our research and
development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory,
marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and
reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and
strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or
strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the
need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding
revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other
statements that are not historical facts. Words such as anticipate,'' believe,''
"contemplate," continue,'' could,''
estimate,'' expect,'' "hope," intend,''
may,'' might,'' plan,''
potential,'' predict,'' project,''
should,'' target,'' "will", would'' and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant
challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks
associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay
in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to
commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates;
development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our
products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture;
our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks
associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related
to our common stock, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and
uncertainties affecting the Company including those described in the "Risk Factors" section included in our Annual Report
on Form 10-K for the year ended December 31, 2020 filed with the SEC and in our other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any
forward-looking statement, whether as a result of new information, future events or otherwise.
and "Y-mAbs" are registered trademarks of Y-mAbs Therapeutics, Inc.